Third Harmonic Bio, Inc. (THRD)

11.90 -0.40 (-3.25%) At close: 04:00PM EDT

Third Harmonic Bio, Inc.

1700 Montgomery Street
Suite 210
San Francisco, CA 94111
United States
(209) 727-2457
https://www.thirdharmonicbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Natalie C. Holles	CEO & Director	942.4k	N/A	1973
Ms. Julie Person	Chief Administrative Officer	574k	N/A	1974
Dr. Edward R. Conner M.D.	Chief Medical Officer	672k	N/A	1973
Mr. Christopher Murphy	Chief Financial & Business Officer	N/A	N/A	1984
Mr. Steven P. Sweeney	Senior Vice President of Development Operations	N/A	N/A	N/A
Ommer Chohan	Treasurer & Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Corporate governance

Third Harmonic Bio, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.